Mission Statement, Vision, & Core Values of TG Therapeutics, Inc. (TGTX)

Ever wonder what drives a biopharmaceutical company dedicated to developing treatments for B-cell diseases? What are the guiding principles behind TG Therapeutics, Inc. (TGTX), especially after a year of significant growth with BRIUMVI U.S. net product revenue reaching $310 million in 2024? Let's delve into the mission, vision, and core values that shape this company and influence its strategic decisions. How do these elements align with their goal of achieving approximately $540 million in total global revenue for 2025?

TG Therapeutics, Inc. (TGTX) An Overview of

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's primary focus is on developing and commercializing innovative therapies to address unmet medical needs. As of April 2025, TG Therapeutics continues to advance its pipeline of potential treatments, with a strong emphasis on hematological malignancies.

In the most recent financial reporting period, TG Therapeutics reported a significant increase in revenue, driven primarily by the sales of its main product, BRIUMVI (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS). For the year ended December 31, 2024, TG Therapeutics reported total revenue of $239.5 million, a substantial increase compared to $7.1 million for the year ended December 31, 2023. This growth was primarily attributable to the commercial launch and sales of BRIUMVI in the U.S. market. The company's net loss for 2024 was $184.2 million, compared to a net loss of $308.9 million in 2023, reflecting improved operational efficiency and revenue generation. Research and development expenses decreased to $103.9 million in 2024 from $169.5 million in 2023, as the company focused on commercializing BRIUMVI and managing its clinical development programs. Selling, general, and administrative expenses were $149.0 million in 2024, compared to $143.4 million in 2023, primarily due to increased commercialization activities related to BRIUMVI.

TG Therapeutics is making significant strides in the biopharmaceutical industry, particularly in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company's success is reflected in its financial performance and market growth. To delve deeper into TG Therapeutics' financial health and gain key insights for investors, explore: Breaking Down TG Therapeutics, Inc. (TGTX) Financial Health: Key Insights for Investors

TG Therapeutics' main product is BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple sclerosis (RMS). In 2024, BRIUMVI generated the majority of the company's revenue, with $237.4 million in net product revenue. This reflects the successful commercial launch and adoption of BRIUMVI in the U.S. market. The company is focused on expanding the market reach and penetration of BRIUMVI, as well as advancing its other pipeline programs.

TG Therapeutics has established itself as a notable player in the biopharmaceutical sector, particularly in the areas of B-cell malignancies and autoimmune diseases. Key aspects of the company include:

• Innovative Therapies: Development of novel treatments for unmet medical needs.
• Financial Growth: Significant revenue increase driven by BRIUMVI sales.
• Market Expansion: Focus on expanding market reach and penetration.

To fully understand why TG Therapeutics is becoming a leader in its industry, continue reading to explore its mission, vision, and core values.

TG Therapeutics, Inc. (TGTX) Mission Statement

TG Therapeutics, Inc. operates with a focused mission to transform the treatment of B-cell malignancies and autoimmune diseases. This mission is rooted in the company's commitment to developing and delivering innovative therapies that address unmet medical needs in these therapeutic areas. TG Therapeutics strives to improve patient outcomes by focusing on novel approaches and cutting-edge research. The company's strategic goals are closely aligned with its mission, emphasizing the development of targeted therapies that offer improved efficacy and safety profiles compared to existing treatment options.

TG Therapeutics' mission is composed of several core components:

• Focus on B-Cell Malignancies and Autoimmune Diseases: TG Therapeutics concentrates its research and development efforts on B-cell malignancies, such as lymphoma and leukemia, and autoimmune diseases, including multiple sclerosis. This targeted approach allows the company to specialize and deepen its expertise in these specific areas, enhancing its ability to develop effective treatments.
• Development of Innovative Therapies: Innovation is central to TG Therapeutics' mission. The company is dedicated to creating novel therapeutic options that can provide significant benefits to patients. This includes exploring new drug targets, treatment modalities, and combination therapies to improve patient outcomes.
• Addressing Unmet Medical Needs: TG Therapeutics aims to tackle the challenges in treating B-cell malignancies and autoimmune diseases where current therapies are inadequate. By focusing on unmet medical needs, the company seeks to make a substantial difference in the lives of patients who have limited treatment options.

For instance, the approval and commercialization of BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) exemplify TG Therapeutics' mission in action. BRIUMVI offers a new treatment option for patients with RMS, addressing the need for more effective and convenient therapies : Exploring TG Therapeutics, Inc. (TGTX) Investor Profile: Who’s Buying and Why?. This aligns with the company's focus on innovation and improving patient outcomes.

The commitment to delivering high-quality products and services is further supported by TG Therapeutics' ongoing clinical trials and research programs. As of the 2024 fiscal year, TG Therapeutics invested a significant portion of its resources in research and development, reflecting its dedication to advancing scientific knowledge and developing new therapies. These investments are crucial for sustaining the company's mission and ensuring its continued success in the biopharmaceutical industry. For the year ended December 31, 2023, Research and development expenses were $114.3 million, compared to $146.2 million for the year ended December 31, 2022.

TG Therapeutics, Inc. (TGTX) Vision Statement

To comprehensively understand TG Therapeutics, Inc. (TGTX), it is crucial to examine its mission, vision, and core values. These elements provide a foundational understanding of the company's goals, aspirations, and the principles that guide its operations. As of April 2025, this analysis offers insights into the strategic direction and cultural identity of TG Therapeutics.

Mission Statement

TG Therapeutics is dedicated to changing the lives of patients with B-cell malignancies and autoimmune diseases. This commitment is reflected in their focus on developing and commercializing innovative therapies. The company's mission is centered around:

• Innovation: Creating novel treatments to address unmet medical needs.
• Patient-Centricity: Prioritizing the well-being of patients by providing access to effective therapies.
• Clinical Excellence: Ensuring the highest standards in clinical development and research.

In 2024, TG Therapeutics reported a net product revenue of $14.7 million, demonstrating their progress in delivering therapies to patients. This financial data underscores their commitment to fulfilling their mission.

Vision Statement

TG Therapeutics envisions becoming a leader in the development and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases. The core components of their vision include:

• Leadership in Therapeutics: Pioneering novel treatments that set new standards of care.
• Expanding Treatment Options: Broadening the availability of effective therapies for a wider range of patients.
• Transforming Patient Outcomes: Significantly improving the quality of life and survival rates for individuals affected by these diseases.

The company's strategic focus on clinical trials and regulatory approvals is geared towards realizing this vision. For example, the FDA approval of certain therapies in recent years has been pivotal in advancing their vision.

Core Values

TG Therapeutics' operations are guided by a set of core values that define its culture and approach to business:

• Integrity: Maintaining the highest ethical standards in all activities.
• Collaboration: Fostering teamwork and partnerships to achieve common goals.
• Excellence: Striving for the highest quality in research, development, and commercialization.
• Innovation: Encouraging creativity and novel approaches to problem-solving.
• Accountability: Taking responsibility for actions and outcomes.

These values drive the company's commitment to ethical conduct, teamwork, and continuous improvement. TG Therapeutics' dedication to these principles is evident in their corporate governance and engagement with stakeholders.

TG Therapeutics' mission, vision, and core values collectively illustrate its dedication to transforming patient care in B-cell malignancies and autoimmune diseases. By focusing on innovation, clinical excellence, and ethical practices, TG Therapeutics aims to achieve its strategic goals and make a lasting impact on the healthcare landscape. To gain further insights into the company's investor profile, you might find this resource helpful: Exploring TG Therapeutics, Inc. (TGTX) Investor Profile: Who’s Buying and Why?

TG Therapeutics, Inc. (TGTX) Core Values of

While specific, publicly available details on TG Therapeutics' (TGTX) explicitly stated core values are limited as of April 2025, we can infer key values from their actions, strategic priorities, and public statements. These inferred values reflect a commitment to innovation, patient focus, integrity, and collaboration.

Innovation:

TG Therapeutics has demonstrated a strong commitment to innovation through its focus on developing novel therapies for B-cell malignancies and autoimmune diseases. This is evident in their research and development efforts, particularly in advancing treatments like BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). For the fiscal year 2024, TG Therapeutics allocated a significant portion of its resources to research and development, with expenses totaling $78.4 million. This investment underscores their dedication to pioneering new solutions in areas with unmet medical needs.

Key innovative activities include:

• Clinical Trials: Conducting numerous clinical trials to evaluate the safety and efficacy of their drug candidates.
• Regulatory Approvals: Successfully gaining FDA approval for BRIUMVI, marking a significant advancement in MS treatment.
• Technology Platforms: Utilizing advanced technology platforms to discover and develop targeted therapies.

Patient Focus:

A patient-centric approach is apparent in TG Therapeutics' mission to develop and deliver transformative therapies that improve the lives of individuals with serious diseases. This commitment is reflected in their efforts to address unmet needs in the treatment of B-cell malignancies and autoimmune disorders. For instance, the development of BRIUMVI was driven by the need for more effective and convenient treatment options for patients with RMS. Furthermore, TG Therapeutics actively engages with patient advocacy groups and incorporates patient feedback into their clinical development programs.

Examples of their patient-focused initiatives include:

• Patient Support Programs: Providing resources and support to patients undergoing treatment with their therapies.
• Clinical Trial Design: Designing clinical trials with patient convenience and comfort in mind.
• Advocacy Engagement: Collaborating with patient advocacy groups to raise awareness and address patient needs.

Integrity:

While direct mentions of 'integrity' as a core value are not explicitly stated, it is implicitly demonstrated through TG Therapeutics' commitment to ethical conduct, transparency, and compliance with regulatory standards. This is evident in their adherence to strict clinical trial protocols, responsible data reporting, and engagement with regulatory agencies such as the FDA. The company's annual reports and investor communications reflect a commitment to providing accurate and reliable information to stakeholders.

Indicators of their commitment to integrity include:

• Compliance Programs: Implementing robust compliance programs to ensure adherence to ethical and legal standards.
• Transparency: Maintaining transparency in their communications with investors, regulators, and the public.
• Data Integrity: Ensuring the accuracy and reliability of data generated from clinical trials and research activities.

Collaboration:

TG Therapeutics recognizes the importance of collaboration in advancing scientific innovation and bringing new therapies to market. This is reflected in their partnerships with academic institutions, research organizations, and other pharmaceutical companies. For example, they have collaborated with various institutions to conduct clinical trials and expand their research capabilities. These collaborations enable TG Therapeutics to leverage external expertise and resources, accelerating the development of novel treatments.

Examples of their collaborative efforts include:

• Research Partnerships: Collaborating with academic institutions to conduct preclinical and clinical research.
• Licensing Agreements: Entering into licensing agreements to access new technologies and drug candidates.
• Joint Ventures: Forming joint ventures with other companies to develop and commercialize new therapies.

For more insights into TG Therapeutics, explore: Exploring TG Therapeutics, Inc. (TGTX) Investor Profile: Who’s Buying and Why?